COP9 signalosomin alayksikkö C
Best matches for COP9 signalosome in human:
Inhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo.
Asare Y et al. Proc Natl Acad Sci U S A.
(2017)
Roles of Multifunctional COP9 Signalosome Complex in Cell Fate and Implications for Drug Discovery.
Li P et al. J Cell Physiol.
(2017)
Targeted inhibition of the COP9 signalosome for treatment of cancer.
Schlierf A et al. Nat Commun.
(2016)
(Suom: Otan yhden esimerkin, jota alussa tarjotaan: Siinä kerrotaan miten tietämystä signalosomin alakomponenteista voidaan hyödyntää anti-syöpäterapiaan ja lääkekehittelyyn. Tämä perustuu siihen että CLR aktiivisuus on usein poikkeavaa syövässä)
/ESIMERKKI, jossa mainitaan CSN5, COP9 alayksikkö. Vaikuttaa siltä että tämä on se JAMM ryhmän deubkitinaasi ja tunnettu myös nimellä COPS5 tai JAB1, MOV-34, SGN5 ja sitä koodaa geeni 8q13.1 COPS5.
JAB/CSN5 tekee CLR- deneddylaation.
JAB1 tarkoittaa Jun Activation domain Binding protein .
Jos CSN5 ilmenemä vaimennetaan. lisääntyy p53 ja BAX.
https://www.ncbi.nlm.nih.gov/pubmed/27774986
Nat Commun. 2016 Oct 24;7:13166. doi: 10.1038/ncomms13166.
Targeted inhibition of the COP9 signalosome for treatment of cancer.
Schlierf A1, Altmann E1, Quancard J1, Jefferson AB1, Assenberg R1, Renatus M1, Jones M1, Hassiepen U1, Schaefer M1, Kiffe M1, Weiss A1, Wiesmann C1, Sedrani R1, Eder J1, Martoglio B1.
Abstract
The COP9 signalosome
(CSN) is a central component of the activation and remodelling cycle of
cullin-RING E3 ubiquitin ligases (CRLs), the largest enzyme family of
the ubiquitin-proteasome system in humans.
CRLs are implicated in the regulation of numerous cellular processes,
including cell cycle progression and apoptosis, and aberrant CRL
activity is frequently associated with cancer. Remodelling of CRLs is
initiated by CSN-catalysed cleavage of the ubiquitin-like activator
NEDD8 from CRLs. Here we describe CSN5i-3, a potent, selective and
orally available inhibitor of CSN5, the proteolytic subunit of CSN. The
compound traps CRLs in the neddylated state, which leads to inactivation
of a subset of CRLs by inducing degradation of their substrate
recognition module. CSN5i-3 differentially affects the viability of
tumour cell lines and suppresses growth of a human
xenograft in mice. Our results provide insights into how CSN regulates
CRLs and suggest that CSN5 inhibition has potential for anti-tumour
therapy.
Inga kommentarer:
Skicka en kommentar